<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089970</url>
  </required_header>
  <id_info>
    <org_study_id>637013</org_study_id>
    <secondary_id>1K23HL127185-01A1</secondary_id>
    <nct_id>NCT03089970</nct_id>
  </id_info>
  <brief_title>Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients</brief_title>
  <official_title>Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory virus infections cause a majority of asthma exacerbations in the fall to spring&#xD;
      months. Current diagnostic platforms for respiratory viruses have limitations including cost,&#xD;
      availability, and invasiveness. The use of noninvasive breath collection to analyze breath&#xD;
      metabolites may be used to differentiate virus-infected asthmatics from other causes of acute&#xD;
      asthma exacerbations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breath metabolite differences between groups</measure>
    <time_frame>36 months</time_frame>
    <description>Metabolites from breath will be identified and quantified using gas chromatography-mass spectrometry; these will be compared between groups. Specific breath metabolites include isoprostane, linear and branched alkanes (C6-C9), alcohols, and thiol-containing moieties. However, we will also measure metabolites in an un-targeted manner.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Upper Respiratory Tract Infections, Asthma, Exhaled Breath</condition>
  <arm_group>
    <arm_group_label>Healthy asthma</arm_group_label>
    <description>Asthmatic patients not with an exacerbation, i.e., stable asthmatics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhinovirus-infected asthmatics</arm_group_label>
    <description>Asthmatics with an exacerbation and associated rhinovirus infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza A-infected asthmatics</arm_group_label>
    <description>Asthmatics with an exacerbation and associated influenza A infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Exhaled breath condensate collection</intervention_name>
    <description>Breath from humans is cooled, condensed, and collected</description>
    <arm_group_label>Healthy asthma</arm_group_label>
    <arm_group_label>Influenza A-infected asthmatics</arm_group_label>
    <arm_group_label>Rhinovirus-infected asthmatics</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Exhaled breath condensate&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with asthma with or without an acute exacerbation will be recruited&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Asthma, Age ≥12, Symptoms/signs of an early asthma exacerbation, Ability to provide&#xD;
             exhaled breath condensate (EBC) x15 min, Body mass index (BMI) ≥18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic lung diseases other than asthma (e.g., chronic obstructive pulmonary disease&#xD;
             [COPD], lung cancer, fibrotic lung disease, etc.), Smoking in the past 7 days, Eating&#xD;
             or non-clear liquids &lt;4 hrs prior to EBC collection, Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schivo, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Ceneter</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

